Differences in persistence of measles, mumps, rubella, diphtheriaand tetanus antibodies between children with rheumatic disease and healthy controls: A retrospective cross-sectional study

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 948-954

  Heijstek, Marloes W ^a   Van Gageldonk, Pieter G M ^b   Berbers, Guy A M ^b   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; GLUCOCORTICOID; IMMUNOGLOBULIN G ANTIBODY; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; MUMPS ANTIBODY; RUBELLA ANTIBODY; TETANUS ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIPHTHERIA; DRUG RESPONSE; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNIZATION; IMMUNOASSAY; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MUMPS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RUBELLA; TETANUS; VACCINATION;

ADOLESCENT; ANTIBODIES, VIRAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; METHOTREXATE; MUMPS; NETHERLANDS; RETROSPECTIVE STUDIES; RUBELLA; SEROEPIDEMIOLOGIC STUDIES; TETANUS; YOUNG ADULT;

EID: 84860917503     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200637     Document Type: Article

References (49)

1. Ada G. Vaccines and vaccination. N Engl J Med 2001;345:1042-53.
2. Oostvogel PM, van Wijngaarden JK, van der Avoort HG, et al. Poliomyelitis outbreak in an unvaccinated community in The Netherlands, 1992-93. Lancet 1994;344:665-70. (Pubitemid 24274315)
3. Davidkin I, Jokinen S, Broman M, et al. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 2008;197:950-6. (Pubitemid 351590022)
4. Peltola H, Jokinen S, Paunio M, et al. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect Dis 2008;8:796-803.
5. Atrasheuskaya AV, Kulak MV, Neverov AA, et al. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. Vaccine 2008;26:2111-18.
6. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
7. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheumatol 2002;16:281-91.
8. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704-12.
9. De Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 1998;121:637-43. (Pubitemid 29023043)
10. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
11. Harmsen T, Jongerius MC, van der Zwan CW, et al. Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps. J Clin Microbiol 1992;30:2139-44.
12. van den Hof S, Beaumont MT, Berbers GA, et al. Antibodies against mumps in The Netherlands as assessed by indirect ELISA and virus neutralization assay. Epidemiol Infect 2003;131:703-9. (Pubitemid 37062892)
13. Tischer A, Andrews N, Kafatos G, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiol Infect 2007;135:787-97.
14. van den Hof S, van Gageldonk-Lafeber AB, van Binnendijk RS, et al. Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay. Vaccine 2003;21:4210-14.
15. Andrews N, Pebody RG, Berbers G, et al. The European Sero-Epidemiology Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol Infect 2000;125:127-41.
16. van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008;335:79-89.
17. Steens A, Mollema L, Berbers GA, et al. High tetanus antitoxin antibody concentrations in the Netherlands: a seroepidemiological study. Vaccine 2010;28:7803-9.
18. Di Giovine P, Pinto A, Olander RM, et al. External quality assessment for the determination of diphtheria antitoxin in human serum. Clin Vaccine Immunol 2010;17:1282-90.
19. Skendzel LP. Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 1996;106:170-4. (Pubitemid 26277203)
20. von Hunolstein C, Aggerbeck H, Andrews N, et al. European sero-epidemiology network: standardisation of the results of diphtheria antitoxin assays. Vaccine 2000;18:3287-96. (Pubitemid 30408205)
21. de Melker HE, van den Hof S, Berbers GA, et al. Evaluation of the national immunisation programme in the Netherlands: immunity to diphtheria, tetanus, poliomyelitis, measles, mumps, rubella and Haemophilus influenzae type b. Vaccine 2003;21:716-20. (Pubitemid 36091985)
22. Rümke HC, Visser HK. [Childhood vaccinations anno 2004. I. Effectiveness and acceptance of the Dutch National Vaccination Programme]. Ned Tijdschr Geneeskd 2004;148:356-63.
23. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
24. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002;29:2555-7. (Pubitemid 35416961)
25. Williams GW, Steinberg AD, Reinertsen JL, et al. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med 1978;88:729-34. (Pubitemid 8351370)
26. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:623-5. (Pubitemid 34717774)
27. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4. (Pubitemid 43131992)
28. Elkayam O, Paran D, Caspi D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147-53. (Pubitemid 34028344)
29. Kashef S, Ghazizadeh F, Derakhshan A, et al. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol 2008;5:181-4.
30. Ristow SC, Douglas RG Jr, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978;88:786-9. (Pubitemid 8351380)
31. Wiesik-Szewczyk E, Romanowska M, Mielnik P, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010;29:605-13.
32. ter Borg EJ, Horst G, Hummel E, et al. Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol 1991;59:117-28.
33. Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 2009;48:144-8.
34. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-65.
35. Ward BJ, Boulianne N, Ratnam S, et al. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995;172:1591-5.
36. Viana PO, Ono E, Miyamoto M, et al. Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen. J Clin Immunol 2010;30:574-82.
37. Hanna-Wakim R, Yasukawa LL, Sung P, et al. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis 2008;197:1669-75. (Pubitemid 351919630)
38. Tosh PK, Kennedy RB, Vierkant RA, et al. Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity. Viral Immunol 2009;22:451-6.
39. de Haas R, van den Hof S, Berbers GA, et al. Prevalence of antibodies against rubella virus in The Netherlands 9 years after changing from selective to mass vaccination. Epidemiol Infect 1999;123:263-70. (Pubitemid 29509324)
40. Miyamoto M, Ono E, Barbosa C, et al. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus 2011;20:736-44.
41. Poland GA, Ovsyannikova IG, Jacobson RM. Vaccine immunogenetics: bedside to bench to population. Vaccine 2008;26:6183-8.
42. Tan PL, Jacobson RM, Poland GA, et al. Twin studies of immunogenicity -determining the genetic contribution to vaccine failure. Vaccine 2001;19:2434-9. (Pubitemid 32234254)
43. Prahalad S, Glass DN. A comprehensive review of the genetics of juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2008;6:11.
44. Thomson W, Barrett JH, Donn R, et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology (Oxford) 2002;41:1183-9. (Pubitemid 35203549)
45. Cunningham-Rundles C. Autoimmune manifestations in common variable immunodeficiency. J Clin Immunol 2008;28 (Suppl 1):S42-5.
46. Morbach H, Girschick HJ. Do B cells play a role in the pathogenesis of juvenile idiopathic arthritis? Autoimmunity 2009;42:373-5.
47. Prelog M, Schwarzenbrunner N, Sailer-Höck M, et al. Premature aging of the immune system in children with juvenile idiopathic arthritis. Arthritis Rheum 2008;58:2153-62. (Pubitemid 351988109)
48. Grubeck-Loebenstein B. Fading immune protection in old age: vaccination in the elderly. J Comp Pathol 2010;142 (Suppl 1):S116-19.
49. de Voer RM, Mollema L, Schepp RM, et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS ONE 2010;5:e12144.